A Phase II study of ERK inhibition by ulixertinib (BVD-523) in Metastatic Uveal Melanoma.
Buchbinder EI, Cohen JV, Tarantino G, Lian CG, Liu D, Haq R, Hodi FS, Lawrence DP, Giobbie-Hurder A, Knoerzer D, Sullivan RJ.
Buchbinder EI, et al. Among authors: tarantino g.
Cancer Res Commun. 2024 Apr 29. doi: 10.1158/2767-9764.CRC-24-0036. Online ahead of print.
Cancer Res Commun. 2024.
PMID: 38683104
Free article.